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Our aim was to investigate bile duct cancer specific fusion genes found in patient's specimens. We extracted total RNA from five bile duct cancer tissues and normal tissues from the same patients. We performed RNA sequencing and the result data was analyzed using ChimeraScan, Jaffa or Fusionchacher softwares to detect gene fusion. We selected one fusion gene that is PUM1-TRAF3. We analyzed the expression of a selected fusion gene in 55 bile duct cancer patients and cancer cell lines by conventional PCR and Droplet Digital PCR. We found PUM1-TRAF3 fusion gene in 28 patients out of 55 patients and it has 50.9% frequency.
In order to predict the function of PUM1-TRAF3 in vitro, PUM1-TRAF3 was transfected into SNU1196 to induce overexpression. Expression of PUM1-TRAF3 fusion gene leads to upregulation of EMT markers and cell proliferation, migration, invasion and clonogenicity. These findings indicate the presence of novel fusion genes as well as its possible application for the early diagnosis or prognosis of bile duct cancer. arising from the biliary tract epithelium, and an increasing incidence of CCA has been reported worldwide in recent years. 1 The cure for CCA is attainable by curative radical surgical resection or liver transplantation, but the difficulty in early diagnosis often results in inoperable cases and hence a poor outcome of the patients with a 5-year survival of less than 5% and a median survival period of 6 months in advanced cases. 2 Liver transplantation is useful in the treatment of CCA. However, recurrence of the disease is common due to the unique biological characteristics involved, such as cholangiocyte differentiation and abundant stromal desmoplasia. Due to the lack of an early diagnosis, most patients are not eligible for surgical resection. 3, 4 Therefore, novel treatment strategies against CCA are needed to improve survival, particularly in high-risk subgroups.
Although many frequently mutated genes have been identified in cholangiocarcinoma, such as TP53 (37-44%) and KRAS (17-54%), 5 
RNA Sequencing
Total RNA from human tissues were extracted using an RNeasy Mini Kit (Qiagen, Valentia, CA, US) and mRNA libraries were prepared from 20 to 50 ng, depending on the DV200 value, of the extracted RNA using the capturing chemistry of the 
Fusion identification and analysis
Three fusion detection tools were used to identify cancer somatic fusion:
ChimeraScan (version 0.4. 
Validation of the PUM1_TRAF3 fusion by RT-PCR
Total RNA from human tissues and cell pellets of harvested cultured cells were extracted using an RNeasy Mini Kit (Qiagen) and total RNA extraction from slides was performed using RNeasy FFPE Kit(Qiagen). Human normal pancreas cDNAs were purchased from Ambion (Life Technologies) and Takara. Total RNA was quantified using an ND-1000 Nanodrop spectrometer (NanoDrop Technologies, Wilmington, DE, US). Reverse transcription was performed using Superscript II, RNaseOUT, oligo(dT) primer, and dNTPs (all from Invitrogen, Carlsbad, CA, US).
PCR, using Ex Taq HS DNA polymerase (TaKaRa, Shiga, Japan), was carried out Analysis of the ddPCR data was performed with QuantaSoft analysis software version 1.3.2.0 that accompanied the QX100 droplet reader.
In Situ Proximity ligation Analysis
Sections of paraffin-embedded tissue were deparaffinized in xylene and rehydrated in a graded ethanol series. Endogenous peroxidase activity was blocked by treatment of sections with methanol containing 0.3% hydrogen peroxide at room temperature for 20 minutes. Antigen retrieval was performed in citrate buffer (0.01 M, pH 6.0), followed by blocking in 10% normal donkey serum for 1 hour at room temperature to reduce nonspecific background staining. 
Gene cloning and expression
Fusion transcript sequence was polymerase chain reaction (PCR) amplified from the patient sample using PT3 (forward) 5'-CCA TGT TGT CGG AGT GAA AG-3' and (reverse) 5'-AGA CAG ACC GGT TCA AAT CC-3') primers. PCR amplification consisted of an initiation step at 95℃ for 3 minutes, followed by 37 cycles at 95℃ for 15 seconds, 58.4℃ for 15 seconds, and 72℃ for 4 minutes. The PCR product was eluted and amplified using primer PT4 (forward) 5'-ATT AAG CTT GCG GCC ATG AGC GTT GCA TGT GTC TT-3' and (reverse) 5'-GAT GAA TTC GCG GCC TTG GGA TCG GGC AGA TCC G-3') at 95℃ for 3 minutes, 
Colony formation assay
Colony-forming efficiency was determined using a double-layer soft agar method. A total of 5000 cells were plated in 0.35% agar over a layer of 0.5% agar containing DMEM and 10% FBS in 6-well plates. Cells were incubated for 4 weeks in a CO2 incubator, and colonies were observed under an inverted Olympus MVX10 microscope.
Statistical analysis
Fisher's Exact test was used for calculating statistical significance between the differences of with fusion versus without fusion. The level of statistical significance was set at P < 0.05. Kaplan-Meier survival curves (Kleinbaum and Klein, 2005) were computed via R package. The recurrence-free survival rate was compared among patients with fusion and without fusion to investigate whether fusion event is an indicator of prognosis.
Discovery of Candidate Fusions in Bile Duct cancers
To identify bile duct cancer specific gene mutation, we performed RNA-seq analysis with five pairs of fresh-frozen bile duct cancer and adjacent normal samples. The RNA-seq data was analyzed using three fusion detection tools, including ChimeraScan, FusionCatcher and JAFFA. As a result, a list of 52
candidates results were obtained. To determine somatic fusion in bile duct cancer, fusions found in any normal samples and previously known normal fusions were removed. To select bile duct cancer somatic fusion with reliable and high confidence, we analyzed according to tool with some strategies described in the method section. Moreover, the fusions detected at least two software tools were analyzed additionally. The data was compared with the previously reported gene fusions using ChimerDB2.0, FusionCancer, PanCanFusionV2, and COSMICv77 softwares and cancer-related genes were screened by Sanger Cancer gene census ( Figure 1) . As a result, we selected seven different fusions that were identified in more than two tools. Individual fusions were analyzed with tissue samples previously analyzed for RNA-seq analysis by conventional PCR. To determined site of fusion, Sanger sequencing was also performed. To validate the gene fusion, we constructed a primer to confirm the fusion of backward and forward genes, followed by conventional PCR, and confirmed by Sanger sequencing that the fusion gene was consistent with the RNA-seq data. Among seven fusions, we excluded five fusions whose expression was confirmed in cancer as well as normal tissues adjacent to the cancer. Though we tried to exclude the fusion genes found in normal tissues based on the previously reported data, Five genes were out and only two genes remained. The remaining two fusions ASH1L-DOCK7 and PUM1-TRAF3 were analyzed in cancer tissues. We excluded ASH1L-DOCK7
from future experiments because it is too long to study functions. To confirm that the gene fusion is cancer specific, we analyzed with two normal human pancreatic tissue cDNAs. We were verified using normal human pancreatic cDNA. Because normal bile duct cDNA could not be obtained. Both ASH1L-DOCK7 and PUM1-TRAF3 fusion was occurred in a single tumor sample that was detected in all three fusion finding tools. It is worth to mention that the two candidate fusions were identified in a single patient's tissue (presented as #2150 patient) where the patient diagnosed with intrahepatic cholangiocarcinoma and tumor was recurred and metastasis in liver was also observed. It is likely that the fusion gene related to the outcome of the patient. We analyzed whether the fusion gene was repeatedly observed in patients with other bile duct cancer. inactivation is likely to promote cell survival via NF-κB pathway activation. 13, 14 In order to confirm the expression of PUM1_TRAF3 in a patient tissues(#2150) that conducted RNA sequencing, We performed conventional PCR and it was confirmed that it was expressed only in a cancer tissue (figure 2B). To confirm the fusion site, we performed gel extraction and analysed Sanger sequencing ( figure   2C ). We verified the fusion site in fusion transcripts on chromosome 1 exon18 of PUM1 and chromosome 14 exon10 of TRAF3.
We performed proximal ligation assay(PLA) to identify the presence and 
Recurrent PUM1-TRAF3 Fusion in Cholangiocarcinoma
To determine whether the PUM1-TRAF3 fusion gene is expressed specifically in cancer, we obtained 21 pairs(cancer tissues and its adjacent normal tissues) of bile duct cancer patient's tissues. We performed conventional PCR after extracted total RNA from 22 pairs of tissues and synthesized cDNA. As a result we found PUM1-TRAF3 fusion gene in 7 patients out of 21 patients and only detected in cancer tissue ( figure 3A) . However, Its signal was smeared. We need to find more delicate method to detect fusion transcript. Droplet digital PCR(ddPCR) is a method for performing digital PCR that is based on water-oil emulsion droplet system. PCR amplification of the template molecules occurs in each individual droplet. Prior to droplet generation, cDNA are prepared and using a real-time primer. We analyzed the 22 pairs of patient's tissue using ddPCR including a 2150 patient that was previously analyzed. We can find PUM1-TRAF3 fusion gene in 13 patients out of 22 patients and only detected in cancer tissue but not found in any normal samples ( Figure 3B ). We can detect a larger number of patients expressed PUM1-TRAF3 in ddPCR than conventional PCR. It is due to allow for the sensitive detection of rare targets.
Additionally we obtained formaline-fixed paraffin embedded (FFPE) cancer tissue slides of 33 bile duct cancer patients to determine the clinical significance of the fusion gene and performed ddPCR. As a result we found PUM1-TRAF3 fusion gene in 28 patients out of 55 patients. It was found in patients with bile duct cancer with a 50.9% frequency ( Figure 3C ). 
PUM1-TRAF3 overexpression resulted in Epithelial-Mesenchymal Transition(EMT)
PUM1_TRAF3 is expressed at a high frequency in patients with bile duct cancer and we predicted that it is related to bile duct cancer. We investigated fusion mRNA expression by conventional PCR to confirm whether the fusion gene is expressed in 7 bile duct cancer cell line including SNU245, SNU308, SNU478, SNU869, SNU1079, SNU1196 and HUCCT1. No fusion gene was found in any cell line compared with house keeping gene, Glyceraldehyde 3-phosphate dehydrogenase(GAPDH) which is often used as control ( Figure 4A ).
We selected SNU1196 which was derived from Klatskin tumour arising in the hepatic duct bifurcation and mutations of p15, p16 and p53 genes was found in SNU1196. In order to predict the function of PUM1-TRAF3 in vivo, we synthesized the full sequence of PUM1-TRAF3 found in the #2150 patient by conventional PCR, inserted it into the vector including FLAG which is hydrophilic 8-amino acid peptide that is fused to the recombinant protein of interest, and transfected into SNU1196 to induce overexpression. As a result, we confirmed that the fusion protein was overexpressed by western blot using FLAG antibody which can detect to flag tag and TRAF3antibody which can detect C-terminus of TRAF3.
We were able to identify a band of PUM1-TRAF3 fusion protein at 150kDa size and GAPDH is used as control ( Figure 4B ).
To determine whether it is associated with PUM1 or TRAF3, we have examined protein levels associated with PUM1 such as cyclin B1, cyclin D3, PCNA and CDK2 and protein levels associated with TRAF3 such as NFkB. GAPDH is used as control. As a result, proteins including cyclinB1, D3 and CDK2 level related to PUM1 was not changed and NFkB related to TRAF3 was increased ( Figure 4C ).
NF-κB is widely used by eukaryotic cells as a regulator of genes that control cell proliferation and cell survival. Active NF-κB turns on the expression of genes that keep the cell proliferating and protect the cell from conditions that would otherwise cause it to die via apoptosis. Defects in NF-κB results in increased susceptibility to apoptosis leading to increased cell death. 14, 15 To evaluate whether the phenotypic changes induced by PUM1-TRAF3
reflected a EMT, we investigated the expression of various EMT markers by western blot. As a result, expression of PUM1-TRAF3 fusion protein leads to upregulation of EMT markers including N-cadherin and Slug. Cell adhesion associated protein, ILK, was downregulated in the group transfected fusion gene ( Figure 4D ), suggesting that this fusion gene leads to an epithelial to a mesenchymal transition. 
PUM1-TRAF3 increases cell motility.
We expected that PUM1-TRAF3 fusion gene can cause to increase cell mobility after confirming change in the EMT markers. To investigate whether the change induced by PUM1-TRAF3, we performed proliferation assay using EZ-CYTOX which is to measure the amount of living cells using tetrazolium salt. The WST of EZ-CYTOX is reduced by succinate-tetrazolium reductase which is dehydrogenase, which is active only in living cells, to produce formazan.
Therefore, as the number of living cells in the sample increases, the dehydrogenase activity of the mitochondria increases, and the formazan production increases and the absorbance increases. As a result, a group of transfected with PUM1-TRAF3 slightly increased proliferation ( Figure 5A ).
To investigate whether the cell motility changes induced by PUM1-TRAF3, we We performed multivariate survival analysis using Cox-regression. As a result, the hazard ratio (HR) of fusion gene occurrence to the disease free survival dates was 2.86 with p value of 0.023, stage was 2.69 with p value of 0.041, CA19-9 was 1.00 with p value of 0.011 and resection margin(RM) was 4.57 with p value of 0.002. The patient with fusion gene (PT+) showed significant decrease in DFS compared to the fusion gene negative (PT-) groups (Table 2) . . There was a need to do study that helped in the diagnosis and treatment of bile duct cancer.
Statistical analysis
To identify bile duct cancer specific fusion genes in patient tissues we performed RNA sequencing. The RNA-seq data was analyzed using three fusion detection tools, including ChimeraScan, FusionCatcher and JAFFA. As a result, a list of 52
candidates results were obtained. We performed convestional PCR to confirm the expression of the fusion gene in bile duct cancer tissues. However, except for two which is ASH1L-DOCK7 and PUM1-TRAF3, they were found in normal tissues and excluded. The reason for the expression of the fusion gene in normal tissues is expected to be that the tissue has been removed and mixed with cancer tissue during the process. The remaining two fusions ASH1L-DOCK7 and PUM1-TRAF3 was not expressed adjacent normal tissue. We focused on PUM1-TRAF3 fusion gene due to fact that ASH1L-DOCK7 fusion gene is too long to study functions.
In order to investigate the function of PUM1-TRAF3 fusion gene, FLAG tagged PUM1-TRAF3 was transiently transfected into SNU1196 cells. To confirm the expression of PUM1-TRAF3 fusion gene and changes of EMT markers and proteins related to front and back genes, we performed western blot. We used antibodies tagged with FLAG because we did not have antibodies of detecting fusion protein.
However, we have confirmed that TRAF3 antibody can detect fusion protein as well.
We predict that the PUM1-TRAF3 fusion gene will be associated with TRAF3, because protein level related to PUM1 was not changed and NFkB related to TRAF3 was increased.
We obtained Bile duct cancer tissues and tissue slides. A bile duct cancer tissue slide was more useful to confirm PUM1-TRAF3 expression. Because cancer tissues contain many normal tissues, they could not be detected sensitively when performing
We present a new concept of inferring the oncogenic potential of novel fusion genes identified in tumor samples. This study showed that the PUM1-TRAF3 in tumor samples were expressed compared with normal tissues and functions of PUM1-TRAF fusion gene. To identify bile duct cancer fusion, we performed RNA-seq analysis with five fresh-frozen bile duct cancer samples and we identified bile duct cancer specific fusion gene, PUM1-TRAF3. This fusion is novel and has never been reported in cancers. We verified the fusion point in fusion transcripts on chromosome 1 exon18 of PUM1 and chromosome 14 exon 10 of TRAF3. Fusion protein expression site is in the cytoplasm.
In order to predict the function of PUM1-TRAF3 in vivo, PUM1-TRAF3 was transfected into SNU1196 to induce overexpression. Protein level related to PUM1
was not changed and NFkB related to TRAF3 was increased. Expression of PUM1-TRAF3 fusion gene lead to upregulation of EMT markers and cell adhesion associated protein was downregulated, suggesting that this fusion gene leads to an epithelial to a mesenchymal transition. Overexpression of PUM1-TRAF3 fusion gene increases cell proliferation, migration, invasion and clonogenicity indicating that PUM1-TRAF3 expression increase cell tumorigenicity. This study confirmed that PUM1-TRAF3 fusion as a potent oncoprotein in Bile duct cancer.
We found PUM1-TRAF3 fusion gene in 28 patients out of 55 patients. It was found in patients with bile duct cancer with a 50.9% frequency. A high expression PUM1-TRAF3 fusions in Korean Bile duct cancer patients was identified in our study, is more meaningful than in previous studies. This discovery will bring about a dramatic change in Bile duct cancer diagnosis.
This study confirmed that PUM1-TRAF3 fusion as a potent oncoprotein in Bile -
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